Belite Bio (BLTE) Competitors $82.81 -0.85 (-1.02%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends BLTE vs. ITCI, ROIV, ASND, JAZZ, MDGL, LEGN, ELAN, VKTX, CYTK, and BPMCShould you be buying Belite Bio stock or one of its competitors? The main competitors of Belite Bio include Intra-Cellular Therapies (ITCI), Roivant Sciences (ROIV), Ascendis Pharma A/S (ASND), Jazz Pharmaceuticals (JAZZ), Madrigal Pharmaceuticals (MDGL), Legend Biotech (LEGN), Elanco Animal Health (ELAN), Viking Therapeutics (VKTX), Cytokinetics (CYTK), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical preparations" industry. Belite Bio vs. Intra-Cellular Therapies Roivant Sciences Ascendis Pharma A/S Jazz Pharmaceuticals Madrigal Pharmaceuticals Legend Biotech Elanco Animal Health Viking Therapeutics Cytokinetics Blueprint Medicines Intra-Cellular Therapies (NASDAQ:ITCI) and Belite Bio (NASDAQ:BLTE) are both mid-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, institutional ownership, profitability, media sentiment, analyst recommendations, community ranking, earnings, valuation and risk. Is ITCI or BLTE more profitable? Belite Bio has a net margin of 0.00% compared to Intra-Cellular Therapies' net margin of -14.07%. Intra-Cellular Therapies' return on equity of -9.93% beat Belite Bio's return on equity.Company Net Margins Return on Equity Return on Assets Intra-Cellular Therapies-14.07% -9.93% -8.38% Belite Bio N/A -31.94%-30.73% Does the media favor ITCI or BLTE? In the previous week, Belite Bio had 7 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 18 mentions for Belite Bio and 11 mentions for Intra-Cellular Therapies. Intra-Cellular Therapies' average media sentiment score of 1.21 beat Belite Bio's score of 0.70 indicating that Intra-Cellular Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intra-Cellular Therapies 8 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Belite Bio 2 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, ITCI or BLTE? Belite Bio has lower revenue, but higher earnings than Intra-Cellular Therapies. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Belite Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioIntra-Cellular Therapies$464.37M19.05-$139.67M-$0.87-95.88Belite BioN/AN/A-$31.63M-$1.11-74.60 Do analysts prefer ITCI or BLTE? Intra-Cellular Therapies currently has a consensus target price of $97.23, indicating a potential upside of 16.56%. Belite Bio has a consensus target price of $89.00, indicating a potential upside of 7.47%. Given Intra-Cellular Therapies' higher possible upside, equities analysts plainly believe Intra-Cellular Therapies is more favorable than Belite Bio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Intra-Cellular Therapies 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.85Belite Bio 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, ITCI or BLTE? Intra-Cellular Therapies has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500. Comparatively, Belite Bio has a beta of -1.6, indicating that its share price is 260% less volatile than the S&P 500. Does the MarketBeat Community prefer ITCI or BLTE? Intra-Cellular Therapies received 491 more outperform votes than Belite Bio when rated by MarketBeat users. However, 96.77% of users gave Belite Bio an outperform vote while only 67.84% of users gave Intra-Cellular Therapies an outperform vote. CompanyUnderperformOutperformIntra-Cellular TherapiesOutperform Votes52167.84% Underperform Votes24732.16% Belite BioOutperform Votes3096.77% Underperform Votes13.23% Do insiders and institutionals have more ownership in ITCI or BLTE? 92.3% of Intra-Cellular Therapies shares are held by institutional investors. Comparatively, 0.5% of Belite Bio shares are held by institutional investors. 2.6% of Intra-Cellular Therapies shares are held by insiders. Comparatively, 13.3% of Belite Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryIntra-Cellular Therapies beats Belite Bio on 10 of the 17 factors compared between the two stocks. Ad WealthPressThe Tesla Trade Is Back In BusinessIf you held shares of Tesla throughout 2024, you know It’s been a year of extreme highs and lows… But according to our one expert, new yearly highs are on the horizon… In his words, Tesla is building momentum like in 2020, especially as Trump supports the EV maker. Which is why we’re emailing you now… You see, most people will simply buy shares of Tesla ahead of the election… But as they say “There is more than one way to skin a cat” In fact, we’ve found another way to play shares of Tesla.Discover how to trade Tesla, simply follow this link here. Get Belite Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BLTE vs. The Competition Export to ExcelMetricBelite BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.53B$6.53B$5.15B$8.74BDividend YieldN/A8.15%5.18%4.08%P/E Ratio-74.604.4062.6013.00Price / SalesN/A377.651,277.9088.72Price / CashN/A51.2139.7935.27Price / Book22.569.636.455.92Net Income-$31.63M$154.43M$119.73M$225.73M7 Day Performance2.13%-9.46%-5.13%-1.34%1 Month Performance47.88%-7.27%-2.71%1.15%1 Year Performance122.61%28.13%31.08%24.02% Belite Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BLTEBelite Bio1.3081 of 5 stars$82.81-1.0%$89.00+7.5%+122.7%$2.53BN/A-74.6020Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoverageITCIIntra-Cellular Therapies4.5171 of 5 stars$88.49-3.4%N/A+51.6%$9.38B$612.78M-101.71560Insider SellingPositive NewsROIVRoivant Sciences3.4265 of 5 stars$11.64-1.4%N/A+24.2%$8.73B$124.79M2.09860Analyst ForecastNews CoverageASNDAscendis Pharma A/S3.0664 of 5 stars$127.67-0.6%N/A+35.3%$7.79B$288.08M-13.71640Analyst DowngradeShort Interest ↑News CoverageJAZZJazz Pharmaceuticals4.9331 of 5 stars$127.74+0.5%N/A-0.1%$7.68B$3.83B17.992,800Insider SellingMDGLMadrigal Pharmaceuticals4.3258 of 5 stars$339.04-0.2%N/A+71.1%$7.41BN/A-13.5290Positive NewsLEGNLegend Biotech1.8484 of 5 stars$40.18+0.3%N/A-39.9%$7.30B$285.14M-51.511,800Earnings ReportAnalyst ForecastShort Interest ↑Analyst RevisionNews CoverageELANElanco Animal Health3.5228 of 5 stars$14.12-1.1%N/A+21.5%$7.05B$4.42B35.309,300Short Interest ↑VKTXViking Therapeutics4.5165 of 5 stars$60.60-3.8%N/A+370.8%$7.02BN/A-65.1620CYTKCytokinetics3.8651 of 5 stars$56.19-4.1%N/A+58.5%$6.92B$7.53M-10.44250Insider SellingBPMCBlueprint Medicines3.0865 of 5 stars$96.62-3.3%N/A+41.6%$6.34B$249.38M-45.79640Analyst ForecastShort Interest ↑News Coverage Related Companies and Tools Related Companies ITCI Alternatives ROIV Alternatives ASND Alternatives JAZZ Alternatives MDGL Alternatives LEGN Alternatives ELAN Alternatives VKTX Alternatives CYTK Alternatives BPMC Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:BLTE) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Belite Bio, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Belite Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BLTE Stock Alerts